William Rees Email & Phone Number

Gaithersburg, Md, Us

Dublin, Ireland, Ie

Thousand Oaks, Ca, Us

* Manage 3-6 clinical assay development staff supporting o Specializing in flow cytometry, immunoassay and qPCR platforms/assays in blood and tissueo Delivered derived assay data and analyses for 10 clinical study reports for 5 Inflammation and 3 Immuno-oncology therapeutic candidateso Validation of flow cytometric receptor occupancy and immunophenotyping assays supporting secondary endpoint objectives in 3 Phase 2 clinical trials* Inflammation Molecular Sciences & Computational Biology representative to Global Development Teams for 3 Inflammation/autoimmunity Global Development (Ph1 and II) and 2 Immuno-oncology Early Development (PhI) assetso Recommend, integrate and execute PD/biomarker/PHC strategy in Phase I and II clinical trialso Manage internal and outsourced execution of PD/biomarker study execution/QC/analysis deliverableso Author Contributing Scientist Reports and Clinical Pharmacodynamics modules for Clinical Study Reports, exploratory statistical analysis plans, exposure-response PK/PD modeling o Present Ph I clinical effects, PK, PD and safety for 2 clinical assets at international meetings and lead publication* Translational clinical research collaborator supporting identification/prioritization of new targets and pathobiological characterization of Inflammatory Bowel Disease (IBD) and Asthma patient subsets for PHCo Director of 5 year, 1.6M+ external research alliance with external IBD clinical researcher and KOL. Scientific advisor to Asthma PHC strategy team.o Leader of multidisciplinary team producing and analyzing high-content gene expression, laser scanning cytometry * Principal Investigator Amgen Washington Leukopheresis/Phlebotomy Blood Donor Program since 2006.

Thousand Oaks, Ca, Us

* Develop and qualify pharmacodynamics/target coverage assays, disease response biomarker assays and prognostic response, personalized healthcare (PHC) markers as exploratory endpoints in Ph1 and Ph2 clinical trials of candidate biologic therapies in Inflammation/autoimmunity and Immuno-oncology

* Led multidisciplinary research project to explore basic immunological mechanisms in T cell mediated autoimmune diseases and evaluated soluble, antigen: major histocompatability complex: Fc fusion proteins in the treatment of experimental autoimmune myasthenia gravis (EAMG). A partnered program with 10 FTEs and $3.5 million/year budget. Established clinical research collaboration with key opinion leader in myasthenia gravis biomedical research in the UK. * Developed a scalable production process for an E. coli derived oncoprotein component of a therapeutic cancer vaccine. Evaluated specific T cell responses to oncoprotein and candidate TLR4 /9 adjuvants and developed stable lyophilized formulation with TLR9 agonist. * Designed family of soluble, autoimmune antigen: disease-associated major histocompatability complex: Fc chimeras. Standardized purification and analytical characterization efforts. Managed 2 direct reports in the development of in vitro human T cell potency assay and Lewis rat model of EAMG for proof-of-concept testing. * Introduced state-of-the-art flow cytometric and qPCR T cell assays to cancer vaccine project teams and clinical monitoring group. Developed a robust flow cytometric assay for T cell responses to the WT-1 cancer antigen. Key data supported development of joint venture for development of a WT-1 cancer vaccine.* Served as internal scientific expert on legal/business development team managing patent portfolio and partnering efforts associated with Corixa IP related to treatment of autoimmune diseases.* Developed a potency assay for a late stage cancer vaccine product where previous efforts over 2 years had failed. Determined optimal mouse strain and qualified ELISA assay for transferred to validation group on timeline.

* Engineered murine and human, peptide/MHC tetramer reagents for staining antigen specific, autoimmune and tumor specific T cells. Managed all molecular biology and insect cell line/baculovirus construction and protein expression, purification, multimerization and analytical characterization assays with direct reports. First to demonstrate the presence of WT-1 specific CD8+ T cells in the blood of multiple myeloma patients. Reagents and methods found application in 3 cancer and 3 infectious disease programs.

Denver, Co - Colorado, Us

* Howard Hughes Medical Institute sponsored fellow in the laboratories of Philippa Marrack and John Kappler. * Development of MHC class I and II multimers to detect and track antigen self and non-self (tumor specific antigens) CD8 and CD4 T cells. * Study the biophysical underpinnigs of the differential avidity hypothesis T cell positive and negative thymic selection through study of T cell receptor-MHC interactions.

Doctor Of Philosophy (Ph.D.), Biophysics

Bachelor'S Degree, Biochemistry And Molecular Biology